Evidence map›Paper›PMID 30408343›Full record

ArticleProteomics. Clinical applications2019

Site-to-Site Reproducibility and Spatial Resolution in MALDI-MSI of Peptides from Formalin-Fixed Paraffin-Embedded Samples.

Alice Ly, Rémi Longuespée, Rita Casadonte, Petra Wandernoth, Kristina Schwamborn, Christine Bollwein, Christian Marsching, Katharina Kriegsmann, Carsten Hopf, Wilko Weichert and 4 more

Abstract read
In one paragraph

Article in Proteomics. Clinical applications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed.

  1. Article
  2. MALDI spatial proteomics: a mini review of approaches and techniques.Analytical methods : advancing methods and applications · 2026
    Review
  3. Review
  4. Article
  5. MALDI-MSI: A potential game changer in forensic sciences.Forensic science, medicine, and pathology · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Prospective on Imaging Mass Spectrometry in Clinical Diagnostics.Molecular & cellular proteomics : MCP · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Alice LyBruker Daltonik GmbH, Bremen, Germany.ORCID 0000-0002-0827-6840
Rémi LonguespéeInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Rita CasadonteProteopath GmbH, Trier, Germany.ORCID 0000-0002-9054-4786
Petra WandernothProteopath GmbH, Trier, Germany.
Kristina SchwambornInstitute of Pathology, Technical University of Munich, Munich, Germany.ORCID 0000-0003-3717-0823
Christine BollweinInstitute of Pathology, Technical University of Munich, Munich, Germany.
Christian MarschingCenter for Biomedical Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Mannheim, Germany.
Katharina KriegsmannDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Carsten HopfCenter for Biomedical Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Mannheim, Germany.
Wilko WeichertInstitute of Pathology, Technical University of Munich, Munich, Germany.
Jörg KriegsmannProteopath GmbH, Trier, Germany.
Peter SchirmacherInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Mark KriegsmannInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0002-7319-3646
Sören-Oliver DeiningerBruker Daltonik GmbH, Bremen, Germany.

Funding

BMBF FKZ 131A029FEurostars-2 ProgrammeGerman Aerospace Center 13FH8I03IANCT Gewebebank Heidelberg
6 · The paper itself

Abstract

purposeTo facilitate the transition of MALDI-MS Imaging (MALDI-MSI) from basic science to clinical application, it is necessary to analyze formalin-fixed paraffin-embedded (FFPE) tissues. The aim is to improve in situ tryptic digestion for MALDI-MSI of FFPE samples and determine if similar results would be reproducible if obtained from different sites. EXPERIMENTAL

designFFPE tissues (mouse intestine, human ovarian teratoma, tissue microarray of tumor entities sampled from three different sites) are prepared for MALDI-MSI. Samples are coated with trypsin using an automated sprayer then incubated using deliquescence to maintain a stable humid environment. After digestion, samples are sprayed with CHCA using the same spraying device and analyzed with a rapifleX MALDI Tissuetyper at 50 µm spatial resolution. Data are analyzed using flexImaging, SCiLS, and R.

resultsTrypsin application and digestion are identified as sources of variation and loss of spatial resolution in the MALDI-MSI of FFPE samples. Using the described workflow, it is possible to discriminate discrete histological features in different tissues and enabled different sites to generate images of similar quality when assessed by spatial segmentation and PCA. CONCLUSIONS AND CLINICAL RELEVANCE: Spatial resolution and site-to-site reproducibility can be maintained by adhering to a standardized MALDI-MSI workflow.

Indexed as

FormaldehydeMolecular ImagingParaffin EmbeddingTissue FixationAnimalsHumansIntestinesMiceOvarian NeoplasmsPeptide FragmentsProteomicsReproducibility of ResultsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTeratomaFormaldehydePeptide Fragmentsformalin-fixed paraffin embedded tissueMALDIreproducibilitytissue typingworkflow

Identifiers

PMID30408343
PMCPMC6590241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.